Nothing said here yet.
to join the conversation.
| Duprey Lauren RusckowskiChief Transformation Officer | Sell | 34,535 | $640.3K | Mon, Sep 14 |
| Plump Andrew StewartPresident, R&D | Sell | 116,191 | $2.1M | Wed, Sep 2 |
| Plump Andrew StewartPresident, R&D | Sell | 19,651 | $363.3K | Wed, Aug 19 |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sell | 12,980 | $235.1K | Tue, Aug 18 |
Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to…
Investing.com-- Takeda Pharmaceutical Co., Ltd. (TYO:4502) reported a stronger operating profit for the first half on Thursday, aided by increased cost-cutting measures and sustained weakness in the yen, which boosted returns from overseas sales.
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic…
Takeda Pharmaceutical reported new Phase 4 VERDICT data showing that intravenous ENTYVIO achieved corticosteroid free disease clearance in moderate to severe ulcerative colitis and was associated with a lower risk of UC related complications compared with…
Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base.
WASHINGTON & TOKYO, October 01, 2026--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal.